Navigation Links
ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
Date:1/23/2008

- First phase of development of product to reduce risk of variant

Creutzfeldt-Jakob Disease from plasma product completed on schedule

- Scale-up phase worth $ 1 M to ProMetic - Multi-million dollar long-term agreement to supply prion removal affinity

resin following regulatory approval anticipated by mid-2008

MONTREAL and CAMBRIDGE, United Kingdom, Jan. 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces that its UK-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has successfully completed the first phases of development utilizing Pathogen Removal and Diagnostic Technologies Inc.'s ("PRDT") ligand technology for prion binding and removal from a plasma product for biopharmaceutical use marketed by a major European plasma fractionator. The program, which is progressing on schedule with expected completion of the scale-up phase in June 2008, is worth approximately $ 1 M to ProMetic. This will be followed by a multi-million dollar long-term supply agreement for the prion reduction resin. The supply agreement is in final stage of negotiation and commercial quantities of resin supply could commence as soon as mid-2008, assuming regulatory approval of the product.

The incorporation in this new application of PRDT's proprietary ligand technology, which is licensed exclusively to PBL, ensures the removal of any abnormal prion proteins that may be present in donated plasma. This additional process will add another level of safety to the already established treatment protocols and is particularly relevant since there is no commercially available diagnostic test for detection of the blood-borne form of the variant Creutzfeldt-Jakob disease ("vCJD") agent.

"We have now demonstrated that the use of the prion reduction technology in process applications is practical," stated Dr. Peter Edwardson, Vice-President, Medical Technologies of ProMetic. "We have already commenced scale
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. Vapotherm(R) Announces Validation of U.S. Patent
3. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
4. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
5. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
6. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
7. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
8. Peptimmune Announces First Close of Series D Private Financing
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
11. Vasogen Announces 2007 Year-End Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...PRNewswire/ -- Calbiotech, Inc. announced today th... Research (SBIR) Phase I contract by the U.S. Army...s of the agreement, Calbiotech will develop analyt...ngue virus. ,, Dengue virus is a mosquito-bo...litary forces deployed to tropical areas of the wo...
(Date:11/6/2009)...for Arrowhead’s 2010 Personalized Medicine P... on February 22-24, 2010 in Philadelphia, has been...ighlight key issues in forming partnerships and en... , Minneapolis, MN (PRWEB...uo;s 2010 Personalized Medicine Partnerships Conf...
(Date:11/5/2009)...wswire/ -- The endangered black-footed ferrets inh...are carnivore feeds on prairie dogs. The prairie...ire population die-offs in towns occur. The U.S. ...a ferret breeding program and has been releasing t... habitat. Unfortunately, plague can sweep through...
(Date:11/5/2009)... ThermoGenesis Corp. (Nas...ducts for processing and storing adult stem cells,...iscal 2010. ,, For the quarter ended September ...llion, a 15 percent increase over revenues of $4.5...any said the key contributors to the growth in rev...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...lopers will have the chance to combine their ideas...st annual Games+Learning+Society conference at t...being held by Games And Professional Practice Simu...Distributed Learning (ADL) Co-Lab and a group of i...Speakers include educators and developers from com...
...terman, here are the top 10 reasons to be at the B...hiladelphia. , , 10. You can pick up some great to...he coin of the realm in the BIO exhibit floor, whe...e set up shop. Mini-soccer balls, mini-Capitol dom... Crowd at BIO 9. You can go on a diet. Believe ...
... of GE Healthcare Technologies in Waukesha, will b...on next year as part of the parent company,s effor...n will succeed Bill Castell as head of GE Healthca... of the Waukesha-based GE Healthcare Technologies ... after Immelts promotion to succeed Jack Welch as ...
Other Biology Technology:Education conference to draw together games researchers 2From the BIO floor 2From the BIO floor 3
(Date:11/5/2009)...tate University has been awarded a training grant ...e Foundation under its Integrative Graduation Educ...is the first IGERT grant to be awarded to Kent Sta...Recovery and Reinvestment Act of 2009, runs throug...focuses on environment aquatic resource sensing (E...
(Date:11/4/2009)...ver, BC - Lowly bacteria, it turns out, hold the p...g plants around the world clean up toxic waste on ...cifically RDX, were invented back in World War II ...es. These high-energy compounds are often used to...ersion of TNT. , But with increased knowledge ...
(Date:11/4/2009)...DWOOD CITY, Calif., Oct. 20 Digita...nd authentication solutions, today announced that ...ale (POS) software for quick-service restaurants, ...r NextGen POS and Classic POS solutions. WAND,s qu...etrics to boost cashier accountability and deter u...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Genomic research will enable greener cleanup of military explosive test sites 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 1Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 2Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 3Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 4Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 5Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal 28TM 29 for the Treatment of Fabry Disease 4624 6Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 1Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 2Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 3Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 4Verenium and Add Food Service GmbH Announce Commercial Distribution Partnership for Fuelzyme 28R 29 and Veretase 28TM 29 Enzymes 49583 5
...ifying Bacillus anthracis, the causative agent of ...e U.S. Food and Drug Administration (FDA). The tes... scientists at the U.S. Army Medical Research Inst... its performance and reliability when used with cl...hage Assay was first developed by the Centers for ...
...r Mark Pagani in the Department of Geology and Geo...t detailed history of atmospheric carbon dioxide b...sotopes of carbon in a National Science Foundation... energy we consume, each of us makes a contributio...dioxide and methane, in the Earth,s atmosphere," s...
...ly notice if the outside world suddenly went dark ...ur blinks, even though they cause a similar reduct...y are we not aware of the frequent mini-blackouts ...vered that visual sensitivity begins decreasing im... underlying this process have until now remained u...
Other Biology News:Anthrax test, developed by army and CDC, receives FDA approval 2Anthrax test, developed by army and CDC, receives FDA approval 3Invasive parasite destroying fish species 2Blink, and the brain misses it 2
Biomek FX Laboratory Workstation (High Throughput) from Beckman Coulter
Methlation Analysis/Bisulfite Sequencing from Seqwright
...ncourt offers quick turnaround sequencing of indiv...ow copy and high copy plasmids. Agencourt's world-...ses over 20 million Phred20 bases per day. The ke...e Sequencing service are 24 48 hour sample turnar...
Acridinium Labeling Buffer from Cayman Chemical
Biology Products: